The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Open accessAbstract
BACKGROUND: Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insulin secretion by the remaining β cells in patients with newly diagnosed T1D. METHODS: In a multicenter, randomized, double-blind, placebo-controlled trial, we compared alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause) with placebo in patients with recent onset of T1D. Endpoints were assessed at 24 months and included meal-stimulated C-peptide AUC, insulin use, hypoglycemic events, and immunologic responses. RESULTS: A total of 49 patients were enrolled. At 24 months, or 15 months after the last dose of alefacept, both the 4-hour and the 2-hour C-peptide AUCs were significantly greater in the treatment group than in the control group (P = 0.002 and 0.015, respectively). Exogenous insulin requirements were lower (P = 0.002) and rates of major hypoglycemic events were about 50% reduced (P < 0.001) in the alefacept group compared with placebo at 24 months. There was no apparent between-group difference in glycemic control or adverse events. Alefacept treatment depleted CD4+ and CD8+ central memory T cells (Tcm) and effector memory T cells (Tem) (P < 0.01), preserved Tregs, increased the ratios of Treg to Tem and Tcm (P < 0.01), and increased the percentage of PD-1+CD4+ Tem and Tcm (P < 0.01). CONCLUSIONS: In patients with newly diagnosed T1D, two 12-week courses of alefacept preserved C-peptide secretion, reduced insulin use and hypoglycemic events, and induced favorable immunologic profiles at 24 months, well over 1 year after cessation of therapy. TRIAL REGISTRATION: https://clinicaltrials.gov/ NCT00965458. FUNDING: NIH and Astellas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572 · cited 1×
“Severe iatrogenic hypoglycemia is the most concerning risk of intensive management and leads to substantial morbidity and mortality in T1D (4, 29, 30).”
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Severe iatrogenic hypoglycemia is the most concerning risk of intensive management and leads to substantial morbidity and mortality in T1D (4, 29, 30).”
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationGlycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Self-citationTreatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., et al. (2007) · JAMA · doi:10.1001/jama.297.14.1568 · Cited by 573
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448 · cited 1×
“In recent decades, some clinical trials in new-onset T1D have demonstrated modest or transient preservation of β cell function using generalized or targeted immunomodulation (6–11), but most immunotherapies, as well as dietary intervention, have had no effect (12–17).”
Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2013) · Diabetes · doi:10.2337/db13-0345 · Cited by 411
Self-citationMoran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Self-citationGAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
Fife, B. T., Guleria, I., Gubbels Bupp, M., Eagar, T. N., Tang, Q., Bour-Jordan, H., Yagita, H., Azuma, M., Sayegh, M. H., & Bluestone, J. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061577 · Cited by 325
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Self-citationKeymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 317
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Self-citationEtanercept Treatment in Children With New-Onset Type 1 Diabetes
Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., & Quattrin, T. (2009) · Diabetes Care · doi:10.2337/dc09-0054 · Cited by 280
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Clifford, D. B., Ances, B., Costello, C., Rosen-Schmidt, S., Andersson, M., Parks, D., Perry, A., Yerra, R., Schmidt, R., Alvarez, E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.103 · Cited by 278
Chamian, F., Lowes, M. A., Lin, S.-L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409569102 · Cited by 221
Rigby, M. R., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70111-6 · Cited by 209
Self-citationOrban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2014) · Diabetes Care · doi:10.2337/dc13-0604 · Cited by 209
Self-citationIncidence of Type 1 and Type 2 Diabetes in Adults Aged 30–49 Years
Bruno, G., Runzo, C., Cavallo-Perin, P., Merletti, F., Rivetti, M., Pinach, S., Novelli, G., Trovati, M., Cerutti, F., Pagano, G., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2613 · Cited by 187
Miller, G. T., Hochman, P. S., Meier, W., Tizard, R., Bixler, S. A., Rosa, M. D., & Wallner, B. P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.211 · Cited by 170
Haller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Rosenthal, S. M., Shuster, J. J., Zou, B., Brusko, T. M., Hulme, M. A., Wasserfall, C. H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78492 · Cited by 167
Self-citationAronson, R., Gottlieb, P. A., Christiansen, J. S., Donner, T. W., Bosi, E., Bode, B. W., Pozzilli, P., & the DEFEND Investigator Group (2014) · Diabetes Care · doi:10.2337/dc13-0327 · Cited by 162
Self-citationGottlieb, P. A., Quinlan, S. C., Krause-Steinrauf, H. J., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D., Moran, A., Lachin, J. M., Skyler, J. S., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1349 · Cited by 158
Self-citationGitelman, S. E., Gottlieb, P. A., Rigby, M. R., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M. E., Moore, W. V., Pinckney, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70065-2 · Cited by 156
Self-citationWalter, M., Kaupper, T., Adler, K., Foersch, J., Bonifacio, E. E., & Ziegler, A. (2010) · Diabetes Care · doi:10.2337/dc09-2297 · Cited by 153
Double-Blind Controlled Trial of Azathioprine in Children With Newly Diagnosed Type I Diabetes
Cook, J. J., Hudson, I. L., Harrison, L. C., Dean, B., Colman, P. G., Werther, G. A., Warne, G. L., & Court, J. M. (1989) · Diabetes · doi:10.2337/diab.38.6.779 · Cited by 119
Orban, T., Beam, C. A., Xu, P., Moore, K., Jiang, Q., Deng, J., Müller, S., Gottlieb, P. A., Spain, L. M., Peakman, M., et al. (2014) · Diabetes · doi:10.2337/db14-0047 · Cited by 96
Self-citationPauken, K. E., Jenkins, M. K., Azuma, M., & Fife, B. T. (2013) · Diabetes · doi:10.2337/db12-1475 · Cited by 95
Co-Inhibitory Pathways and Their Importance in Immune Regulation
Murakami, N., & Riella, L. V. (2014) · Transplantation · doi:10.1097/tp.0000000000000169 · Cited by 94
Ambery, P., Donner, T. W., Biswas, N., Donaldson, J., Parkin, J., & Dayan, C. M. (2013) · Diabetic Medicine · doi:10.1111/dme.12361 · Cited by 90
Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis
Krueger, G. G. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.4.431 · Cited by 74
Chamian, F. N., Lin, S., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M. M., Cardinale, I. R., Khatcherian, A., Novitskaya, I., Wittkowski, K. M., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-27 · Cited by 71
Haider, A. S., Lowes, M. A., Gardner, H., Bandaru, R., Darabi, K., Chamian, F. N., Kikuchi, T., Gilleaudeau, P., Whalen, M. S., Cardinale, I. R., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7442 · Cited by 55
Li, R., Lee, J., Kim, M. S., Liu, V., Moulik, M., Li, H., Yi, Q., Xie, A., Chen, W., Yang, L., et al. (2014) · Diabetes · doi:10.2337/db13-1737 · Cited by 28
Scheinfeld, N. S. (2007) · Journal of Dermatological Treatment · doi:10.1080/09546630701247955 · Cited by 22
Cited by
Autoreactive T cells in type 1 diabetes
Pugliese, A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94549 · Cited by 358
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Self-citationNew frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
Quattrin, T., Haller, M. J., Steck, A. K., Felner, E. I., Li, Y., Xia, Y., Leu, J. H., Zoka, R., Hedrick, J. A., Rigby, M. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006136 · Cited by 255
Self-citationWriting Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214
Self-citation
Metadata
- Authors
- Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., Raskin, P., Keyes-Elstein, L., Long, S. A., Kanaparthi, S., Lim, N., Phippard, D., Soppe, C. L., Fitzgibbon, M. L., McNamara, J., Nepom, G. T., Ehlers, M. R., & the Immune Tolerance Network (ITN) T1DAL Study Group
- Venue
- Journal of Clinical Investigation
- Published
- 2015-07-20
- Volume
- 125
- Issue
- 8
- Pages
- 3285-3296
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2106218189
- Cited by
- 291
- References
- 45
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.